Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft monograph: DSIP — submissions

The 4 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-045/2
Series
Public comment period
Version
1.0
Published
14 Sep 2025
Last reviewed
14 Sep 2025
Next review
14 Sep 2026
Identifier
10.71829/cei.cp.45
Certainty
Not rated
Cycle
2025 Q3
Window
22 Jul 2025 – 21 Aug 2025
Status
Closed
Submissions
4

§2Submissions and responses

4 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Abimbola Sotomayor-Ekwueme, PharmD, PhD Reader in Pharmaceutics · submitting on pharmaceutics
DRAFT-DSIP-MONOGRA/001 received 31 Jul 2025

Storage and reconstitution guidance is given without stating what it rests on

The respondent submits on the draft monograph for DSIP. A neuroactive peptide raises a question the reader wants answered early, which is whether the compound reaches the compartment in which it is said to act.

The draft states storage conditions and a period of use after reconstitution. The respondent asks what evidence supports the period, and states that in the absence of a stability study on this presentation the figure is a convention rather than a finding.

The respondent proposes that any in-use period be accompanied by the stability evidence that produced it, or removed.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted in part24 Sep 2025

The secretariat accepts this submission in part. The period is retained where a stability study on a comparable presentation exists and is cited. Where no such study exists the figure is removed rather than annotated, because an annotated figure is still a figure a reader will use.

In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.

Dr Quentin Gwynne-Sarpong, MD, MPH Primary-care research network · submitting on public health
DRAFT-DSIP-MONOGRA/002 received 07 Aug 2025

The population to which the headline estimate applies is not stated with the estimate

The respondent notes that much of the source literature for DSIP is published in one national literature, and submits with that in view.

The draft carries a headline effect estimate in the abstract without the eligibility criteria of the trials that produced it. The respondent states that the estimate applies to a trial population with specific age, comorbidity and baseline criteria, and that a reader will apply it to whoever is in front of them.

The respondent proposes a one-line population statement adjacent to every headline estimate.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted18 Sep 2025

The secretariat accepts this submission. An estimate detached from its population is an estimate of nothing in particular.

Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.

Dr Frideswide Nordhagen, BPharm, PhD University department of pharmacy practice · submitting on pharmacy practice
DRAFT-DSIP-MONOGRA/003 received 12 Aug 2025

The interaction section lists mechanisms rather than interactions

The respondent has read the draft covering DSIP and makes one submission.

The section describes pathways by which an interaction could occur. It does not say which interactions have been observed, in what setting, or with what consequence. A reader dispensing alongside other therapy cannot act on a mechanism.

The respondent proposes that observed interactions be separated from theoretical ones, and that the theoretical ones be labelled as such.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted in part03 Sep 2025

The secretariat accepts the separation and declines to expand the section beyond the evidence.

The interaction section is now divided into interactions reported in clinical use and interactions predicted from mechanism, with the second labelled as prediction. Where neither exists the section says so in one line rather than being padded.

Dr Vasilisa Immelmann, PharmD, PhD Health-technology assessment agency · submitting on regulatory science
DRAFT-DSIP-MONOGRA/004 received 21 Aug 2025

Regulatory status is stated without naming the jurisdiction

Having read the draft monograph on DSIP, the respondent puts one point to the committee.

The draft states that the compound is approved, or not approved, without saying by whom. The respondent, employed by a health-technology assessment body, states that approval status differs between jurisdictions for several compounds in the series and that an unqualified statement will be wrong somewhere.

The respondent proposes that every status statement name the authority and carry the date on which the status was checked.

Declared interest. Employed by a health technology assessment body that has issued guidance on a compound named in the draft.
Secretariat responseAccepted10 Sep 2025

The secretariat accepts this submission. An unattributed status statement is a claim the Institute cannot support.

Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.